Regenovue Plus Regulatory Status: Essential Insights for Professional Sourcing

Regenovue Plus is a hyaluronic acid (HA) dermal filler produced by NeoGenesis Co., Ltd., a South Korean manufacturer. As an HA filler, its intended use falls within aesthetic dermatology for various indications. Professionals sourcing dermal fillers require clear information on product characteristics and the manufacturer's credentials to ensure compliance and product integrity for their clinics. Exploring other products within the Hyaluronic acid dermal filler catalog can provide context on market standards and available options.

The regulatory landscape for aesthetic injectables is rigorous and varies by jurisdiction. For Regenovue Plus:

• KFDA Approval: As a product originating from South Korea, KFDA (Korean Ministry of Food and Drug Safety) approval is the primary domestic regulatory clearance. [VERIFY: KFDA approval status for Regenovue Plus]. This certification ensures the product meets South Korean safety and efficacy standards.
• CE Marking: The CE mark is critical for market entry into the European Union and certain other territories that recognize it. [VERIFY: CE mark status for Regenovue Plus]. A valid CE certificate, issued by an authorized Notified Body, signifies compliance with European health, safety, and environmental protection standards.
• FDA Approval: Achieving FDA (U.S. Food and Drug Administration) approval for aesthetic injectables is a distinct and extensive process. Many Korean-manufactured HA fillers may not hold direct FDA approval for distribution in the United States. [VERIFY: FDA approval status for Regenovue Plus for the U.S. market]. Professionals in the U.S. should verify the specific product's FDA status before sourcing.

Beyond product-specific approvals, the manufacturing facility's adherence to quality management systems is crucial. NeoGenesis Co., Ltd., like other reputable manufacturers of medical devices, is expected to operate under stringent quality controls.

• GMP (Good Manufacturing Practices): GMP certification ensures products are consistently produced and controlled according to quality standards. This minimizes risks inherent in any pharmaceutical production that cannot be eliminated through testing the final product.
• ISO Certifications: ISO 13485 (Medical devices — Quality management systems — Requirements for regulatory purposes) is particularly relevant for medical device manufacturers, demonstrating a commitment to quality and regulatory compliance. [VERIFY: NeoGenesis Co., Ltd. GMP and ISO certifications]. For example, other manufacturers adhere to similar standards, as detailed in guides like the StarFill Regulatory Status: Essential Insights for Professionals.

The legal status of Regenovue Plus varies significantly across global markets:

• European Union (EU) & UK: Market access typically relies on the CE Mark. Post-Brexit, the UK still largely accepts CE-marked medical devices but is developing its own UKCA marking scheme. Professionals should verify current import regulations for their specific EU country or the UK.
• GCC (Gulf Cooperation Council): Countries in the GCC region (e.g., UAE, Saudi Arabia) often require specific local product registration with their respective health authorities, which may existing CE or KFDA approvals as part of their assessment.
• LATAM (Latin America): Market access across Latin American countries is diverse, with each nation having its own health regulatory body (e.g., ANVISA in Brazil, COFEPRIS in Mexico). Local registration is almost always a requirement.
• APAC (Asia-Pacific): Beyond South Korea (KFDA), countries like Australia (TGA), Singapore (HSA), and others in the APAC region have their own regulatory frameworks. KFDA approval can facilitate registration in some neighboring markets, but specific local authorization is generally needed. Further information on other HA filler options can be found for products like Hyaldew.

Professionals sourcing aesthetic injectables, especially internationally, must exercise diligence regarding parallel imports. While often legal, parallel imports can complicate traceability and guarantee of authenticity if not managed through reputable channels. It is critical to ensure the product has been stored and transported according to cold chain requirements and to verify its origin to prevent the introduction of counterfeit or substandard products into your clinic. This extends to other dermal filler brands like D.Fill Medium as well.

To ensure compliance and patient safety, clinics should demand comprehensive documentation from their Regenovue Plus suppliers. Key documents include:

• Certificate of Analysis (CoA): Batch-specific document detailing quality control testing.
• Certificate of Authenticity: Confirmation that the product is original and supplied directly from the manufacturer or an authorized distributor.
• Proof of Cold Chain Compliance: Documentation showing appropriate storage and transport temperatures, especially for temperature-sensitive products.
• Lot Numbers and Expiry Dates: Must be clearly visible and match accompanying documentation.
• Regulatory Certificates: Copies of valid KFDA approval, CE mark certificate, or other relevant market registrations.